• 1
    Axon A, Forman D. Helicobacter gastroduodenitis: a serious infectious disease. BMJ 1997; 314: 14301.
  • 2
    EverhartJE, ed. Digestive Diseases in the United States: epidemiology and Impact. NIH Publication No 94-1447. 1994.
  • 3
    Australian Bureau of Statistics. National Health Survey 2001: Australia’s Health. Canberra: AIHW, 2004.
  • 4
    Sandler R, Everhart J, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 15009.
  • 5
    World Health Organisation. Cancer 2009. Fact Sheet No 297.
  • 6
    Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348: 1504.
  • 7
    Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. A community screening Program for Helicobacter pylori saves money: 10-year follow-up of a randomised controlled trial. Gastroenterology 2005; 129: 19107.
  • 8
    Lane JA, Harvey RF, Murray L, et al. A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population: study design and response rates of the Bristol Helicobacter Project. Control Clin Trials 2002; 23: 32132.
  • 9
    Lane JA, Murray LJ, Noble S, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use and quality of life in the Bristol Helicobacter project: randomised controlled trial. BMJ 2006; 332: 199202.
  • 10
    Dominguez-Munoz JE, Leodolter A, Sauerbruch T, Malfertheiner P. A citric acid solution is an optimal test drink in the 13C-urea breath test for Helicobacter pylori infection. Gut 1997; 40: 45962.
  • 11
    Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ 1989; 298: 302.
  • 12
    Heatley RV, Rathbone BJ. Dyspepsia: a dilemma for doctors? Lancet 1987; 2: 77882.
  • 13
    Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA Technical Review: evaluation of dyspepsia. Gastroenterology 1998; 114: 58295.
  • 14
    Argyrous G. Statistics for Research: With a Guide to SPSS. 7th ed. UK London: Sage, 2005. ISBN 1412919487.
  • 15
    Chiba N, Van Zanten SJOV, Sinclair P, Ferguson RA, Escobido S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002; 324: 10126.
  • 16
    Spiegel BMR, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 127085.
  • 17
    Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008; 336: 6514.
  • 18
    Harvey RF, Spence RW, Lane JA, et al. Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer. Q J Med 2002; 95: 51925.
  • 19
    Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000; 355: 16659.
  • 20
    Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000; 53: 17581.
  • 21
    Jones R, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 4015.
  • 22
    Wildner-Christensen M, Moller HJ, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003; 125: 3729.
  • 23
    Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effect of a community screening for Helicobacter pylori: a 5-year follow-up study. Amer J Gastroenterol 2008; 103: 110613.
    Direct Link:
  • 24
    Hungin APS, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009; 30: 33142.
  • 25
    Avery Jones F, Gummer JWP, Lennard-Jones JE. Clinical Gastroenterology. Oxford and Edinburgh: Blackwell Scientific, 1960; 4705.
  • 26
    Harvey RF, Lane A, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of the effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter Project. BMJ 2004; 328: 1417.
  • 27
    Ford AC, Forman D, Nathan J, Crocombe WD, Axon AT, Moayyedi P. Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. Aliment Pharmacol Ther 2007; 26: 126775.
  • 28
    Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors and non-steroidal anti-inflammatory drugs. Amer J Gastro 2000; 95: 144855.
    Direct Link: